In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...

HER2 (also known as ERBB2) is a key oncogene in breast cancer and is found in 2–4% of patients with non-small-cell lung ...

In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

Abzena, the leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, has announced today that Taylor ...

Receiving Fast Track designation for PYX-201 from the FDA marks a significant milestone for Pyxis Oncology, recognizing our potential to address the significant medical need in R/M HNSCC. This ...

Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of ...

Pyxis Oncology (PYXS) stock rises as the FDA issues fast track designation for its lead asset PYX-201 in head and neck cancer ...

Clinical validation of the Azymetric platform is demonstrated by the accelerated approval of Ziihera® (zanidatamab-hrii), a treatment for advanced HER2-positive biliary tract cancer in adults who have ...

Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors.

Researchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) ...